Company/Investor Contact: Charles Jones CJones & Associates Public Relations 888-557-6480 305-987-7418 cjones@cjonespr.com HEMISPHERX BIOPHARMA ANNOUNCES FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2015 Hemispherx

& Associates Public Relations

BIOPHARMA ANNOUNCES FINANCIAL RESULTS

THE YEAR ENDED DECEMBER 31, 2015

Biopharma Management Team: Reflects Company's Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve

Financial Capital, and Increase Stockholder Value

Call Scheduled for Wednesday, March 30th at 2 PM EDT

- March 29, 2016 - Hemispherx Biopharma (NYSE MKT: HEB) announced its financial results for the year ended December 31, 2015.

The net loss was approximately $15,230,000 or $(0.06) per share as compared to a net loss of $17,450,000 or ($0.09) per share

for the same twelve-month period in 2014. Cash, cash equivalents and marketable securities were approximately $8,910,000 at December

31, 2015 as compared to $16,108,000 as of December 31, 2014.

have made several significant changes in the past few months. On September 16, 2015, our Board appointed Peter Rodino as Lead

Director. In addition, Rodino and William Mitchell, M.D., Ph.D. were each appointed to the Compensation Committee and Corporate

Governance and Nominating Committee. Rodino, Dr. Mitchell and Iraj E. Kiani were each appointed to the Audit Committee.

February 17, 2016, our Board, by majority vote, terminated the employment of Dr. William A. Carter, our Chairman of the Board,

Chief Executive Officer and Chief Scientific Officer. As a result, Dr. Carter also is no longer a director. Dr. Mitchell, one

of our independent directors, was appointed Chairman of the Board.

February 19, 2016, our Board of Directors also made several changes to our executive management team in light of the termination

of Dr. Carter, in order to provide effective and competent leadership that will properly position us to achieve our commercial

goals and increase stockholder value. In this regard, Adam Pascale was named Chief Financial Officer in addition to his current

responsibilities as Chief Accounting Officer. Pascale has been employed with us for 18 years and has more than two decades of

public accounting and prior public company experience. He earned a Bachelor of Arts degree in Accounting and Finance from Rutgers

University. Mr. Pascale served for several years as a CPA prior to joining the Company, and is a member of both the American and

the Pennsylvania Institutes of Certified Public Accountants. Thomas K. Equels, our Company President, resigned as Chief Financial

Officer to make way for Mr. Pascale.

February 25, 2016, our Board appointed Equels to the position of Chief Executive Officer. In that capacity, he is the principal

executive officer of the Company.

have been reexamining our fundamental priorities in terms of direction, corporate culture and our ability to fund

operations. As a result, there have been significant changes at the Company in the past few months. As noted above, we have

made several changes to the Company's executive management team to provide a change in leadership that, management

believes, will properly position the Company to achieve its commercial goals and increase stockholder value. Recent actions

include listing the sale of underutilized assets, aggressively pursuing international sales of clinical grade materials, and

implementing a strong financial austerity plan. We are committed to a focused business plan oriented toward finding senior

co-development partners with the capital and expertise needed to commercialize the many potential therapeutic aspects of our

experimental drug Ampligen and our approved drug Alferon . Management's primary objectives are to generate

stockholder value and deliver much needed therapies to patients.

flagship products include Alferon N Injection and the experimental therapeutic Ampligen . Alferon N Injection is

approved for a category of STD infection, and Ampligen represents an experimental RNA being developed for globally important

viral diseases and disorders of the immune system. Hemispherx' platform technology includes components for potential treatment

of various severely debilitating and life threatening diseases. Alferon LDO (Low Dose Oral) is a formulation under development

targeting influenza.

below charts provide summaries of the clinical indications for both Ampligen and Alferon currently under development.

own and operate a 43,000 sq. ft. FDA approved facility in New Brunswick, NJ to produce Alferon and Ampligen . We also

completed the construction of our $8 million facility enhancement project in 2015 that, upon FDA approval, should provide for

a higher capacity, more cost-effective manufacturing process for the production of Alferon N Injection .

will host a conference call to discuss recent changes to the Company's management and to provide general information regarding

the new strategy for the Company's operations.

digital telephone replay will be available approximately one hour after the conclusion of the call for two weeks until April 13,

callers: (800) 332-6854

callers: (973) 528-0005

Hemispherx Biopharma

Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug

entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection

and the experimental therapeutics Ampligen and Alferon LDO. Ampligen is an experimental RNA nucleic acid being

developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome.

Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening

diseases. Because both Ampligen and Alferon LDO are experimental in nature, they are not designated safe and effective

by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising

its core intellectual property estate and a fully commercialized product (Alferon N Injection ), approved for sale in the

U.S. and Argentina. The FDA approval of Alferon N Injection is limited to the treatment of refractory or recurrent external

genital warts in patients 18 years of age or older. The Company's Alferon N Injection approval in Argentina includes

the use of Alferon N Injection (under the brand name "Naturaferon") for use in any patients who fail, or become

intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and

exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information,

please visit www.hemispherx.net.

information in this press release includes certain "forward-looking" statements including without limitation statements

about additional steps which the FDA may require and Hemispherx may take in continuing to seek commercial approval of the Ampligen

NDA for the treatment of Chronic Fatigue Syndrome in the United States. The production of new Alferon API inventory will

not commence until the capital improvement and validation phases are complete. While the facility is approved by FDA under the

Biological License Application ("BLA") for Alferon , this status will need to be reaffirmed upon the completion

of the facility's enhancements prior to commercial sale of newly produced inventory product. If and when we obtain a reaffirmation

of FDA BLA status and have begun production of new Alferon API, we will need FDA approval as to the quality and stability

of the final product to allow commercial sales to resume in the United States. The final results of these and other ongoing activities

could vary materially from Hemispherx's expectations and could adversely affect the chances for approval of the Ampligen

NDA in the United States and other countries. Any failure to satisfy the FDA regulatory requirements or the requirements of other

countries could significantly delay, or preclude outright, approval of the Ampligen NDA in the United States and other countries.

contained in this news release, other than historical information, should be considered forward-looking and is subject to various

risk factors and uncertainties including, but not limited to, general industry conditions and competition; general economic factors;

the Company's ability to adequately fund its projects; the impact of pharmaceutical industry regulation and healthcare legislation

in the United States and internationally; trends toward healthcare cost containment; technological advances, new products and

patents obtained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the

Company's ability to accurately predict the future market conditions; manufacturing difficulties or delays; dependence on

the effectiveness of the Company's patents and other protections for products; and the exposure to litigation, including

patent litigation, and/or regulatory actions; as well as numerous other factors discussed in this release and in the Company's

filings with the Securities and Exchange Commission. The final results of these efforts could vary materially from Hemispherx's

foregoing release contains forward-looking statements that can be identified by words such as "will be, investigative, interim,

potential" or similar terms, or by express or implied discussions regarding potential efficacy for Hemispherx's Ampligen ,

or regarding potential future revenues from Ampligen . You should not place undue reliance on these statements. Such forward-looking

statements are based on the current beliefs and expectations of Management regarding future events, and are subject to significant

known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying

assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There

can be no guarantee that Ampligen will receive regulatory approval or be commercially successful in the future. In particular,

management's expectations regarding Ampligen could be affected by, among other things, the uncertainties inherent in research

and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory

actions or delays or government regulation generally; the Company's ability to obtain or maintain proprietary intellectual property

protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing

pressures; unexpected manufacturing issues, and other risks and factors described in Hemispherx's filings with the Securities

and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K on file with the U.S. Securities and Exchange

Commission. Hemispherx is providing the information in this press release as of this date and does not undertake any obligation

to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.